Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 15;191(12):5807-10.
doi: 10.4049/jimmunol.1302187. Epub 2013 Nov 15.

Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor

Affiliations

Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor

Hannah E Cummings et al. J Immunol. .

Abstract

Leukotriene C4 (LTC4) and its extracellular metabolites, LTD4 and LTE4, mediate airway inflammation. They signal through three specific receptors (type 1 cys-LT receptor [CysLT1R], CysLT2R, and GPR99) with overlapping ligand preferences. In this article, we demonstrate that LTC4, but not LTD4 or LTE4, activates mouse platelets exclusively through CysLT2R. Platelets expressed CysLT1R and CysLT2R proteins. LTC4 induced surface expression of CD62P by wild-type mouse platelets in platelet-rich plasma (PRP) and caused their secretion of thromboxane A2 and CXCL4. LTC4 was fully active on PRP from mice lacking either CysLT1R or GPR99, but completely inactive on PRP from CysLT2R-null (Cysltr2(-/-)) mice. LTC4/CysLT2R signaling required an autocrine ADP-mediated response through P2Y12 receptors. LTC4 potentiated airway inflammation in a platelet- and CysLT2R-dependent manner. Thus, CysLT2R on platelets recognizes LTC4 with unexpected selectivity. Nascent LTC4 may activate platelets at a synapse with granulocytes before it is converted to LTD4, promoting mediator generation and the formation of leukocyte-platelet complexes that facilitate inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Platelet activation by cys-LTs. PRP from WT mice was stimulated with the indicated agonists. CD62P was assessed by flow cytometry. Results are mean ± SD from 5–10 separate experiments using platelets from one mouse/strain.
Figure 2
Figure 2
Cys-LT receptors involved in LTC4-induced platelet activation. PRP from mice of the indicated genotypes was stimulated with various concentrations of cys-LTs, or with thrombin as a positive control. A. Effect of CysLT2R deletion. B. Effect of CysLT1R deletion. C. Effect of GPR99 deletion. D. Western blot of proteins from human and WT mouse platelets showing bands corresponding to the anticipated molecular sizes of CysLT1R and CysLT2R. Results in A-C are mean ± SD from 3–5 separate experiments.
Figure 3
Figure 3
Involvement of P2Y12 receptors and extracellular nucleotides in CysLT2R-mediated platelet activation. A. Platelets from WT or P2ry12−/− micewere stimulated with the indicated concentrations of cys-LTs or thrombin. CD62P induction was assessed by flow cytometry. B. WT platelets were stimulated with cys-LTs or thrombin in the absence or presence of apyrase. PRP from P2ry12−/− mice was included as a control. C. Release of ADP by stimulated platelets and effects of apyrase and genotypes. Results mean ± SD from 3 separate experiments.
Figure 4
Figure 4
LTC4 amplifies allergen-induced pulmonary inflammation in a platelet, CysLT2R and P2Y12-dependent manner. Mice were sensitized intraperitoneally with OVA/Alum and challenged 3x with 0.1% OVA with or without intranasal LTC4 (2 nmol). A. BAL fluid total cell counts (top) and eosinophil counts (bottom) from mice of the indicated genotypes. B. Effect of platelet depletion (using anti-CD41 vs. an isotype control) of WT mice challenged with OVA ± LTC4 on BAL fluid cell counts and eosinophil counts. Results are mean ± SEM from a single experiment using 5–10 mice/group. Results from a second experiment were similar.

References

    1. Drazen JM, Israel E. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway. Int Arch Allergy Immunol. 1995;107:319–320. - PubMed
    1. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990;343:282–284. - PubMed
    1. Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A. 1994;91:7663–7667. - PMC - PubMed
    1. Han B, Luo G, Shi ZZ, Barrios R, Atwood D, Liu W, Habib GM, Sifers RN, Corry DB, Lieberman MW. Gamma-glutamyl leukotrienase, a novel endothelial membrane protein, is specifically responsible for leukotriene D(4) formation in vivo. Am J Pathol. 2002;161:481–490. - PMC - PubMed
    1. Lee CW, Lewis RA, Corey EJ, Austen KF. Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology. 1983;48:27–35. - PMC - PubMed

Publication types

MeSH terms